Aiml Innovations Inc · CSE:AIML
Aiml Innovations — Investor Presentation (December 2025)
39 slides from Aiml Innovations's investor presentation, Dec 18, 2025
Slide 1: Biometrics Unleashed: Welcome to Health Tech 2.0
CSE: AIML OTCQB: AIMLF FWB: 42FB Paul Duffy || CEO Biometrics Unleashed Welcome to Health Tech 2.0 The Era of Health Intelligence At the dawn of 2025, advancements in Artificial Intelligence (AI), Predictive Analytics (PA), Large Language Models (LLM) and Transformers (GPT) have reset everything to
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain forward-looking statements that involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of AI/ML Innovations Inc., or industry results to be materially different from an
Slide 3: Enabling Healthier Futures: Agenda
Enabling Healthier Futures AGENDA • Our Markets • What We Do & Why it Matters • Year End Milestones • People, Products, • Technology & IP • Regulatory & Quality Management • Commercial Traction • The Year Ahead • Questions & Answers
Slide 4: Before we Start, some Context
Before we Start, some Context There is a Global Cardiovascular Disease (CVD) Crisis ● 1.14 billion people projected to have CVDs by 2050 with 32% of all global deaths are due to CVDs Cite: World Health Organization ● Surge in Global CVD Deaths: Between 1990 and 2021, deaths from cardiovascular disea
Slide 5: Before we Start, some Context, continued
Before we Start, some Context, continued… ECGs (Electrocardiograms) play a critical role enabling early detection, risk assessment, and timely intervention of Cardiovascular Disease (CVD) ECGs reduce mortality, improve outcomes, and empower proactive heart health management—helping to curb the globa
Slide 6: What We Do and Why It Matters
What We Do and Why It Matters We turn raw ECG signals into a powerful, rich, easy-to-analyze data tables. We live at the optimal point of leverage — least input, greatest output. • Between Signal Capture → Signal Exploit lives the fulcrum of every ECG workflow — where leverage is highest and why inp
Slide 7: What We Do and Why It Matters, continued
What We Do and Why It Matters, continued… Our Technology lives between Signal Capture and Signal Exploit. One Engine — Three Synchronized Outputs MaxYield generates a unified stream of clinical intelligence, structured in three precise layers: • Beat-by-beat label matrix — for classification and tri
Slide 8: Regulated Market Opportunity
Regulated Market Opportunity ECG Patch and Holter Monitoring Market Growth Projected Market Size CAGR $6.4 billion, and it is projected to grow to approximately $11.3 billion by 2032 6.1% ● Approximately 100 million electrocardiograms (EKGs/ECGs) are performed annually in the United States ○ Globall
Slide 9: Non-Regulated Market Opportunity
Non-Regulated Market Opportunity Consumer Wearable Technology (Unregulated Market) Projected Market Size CAGR To grow from $82.33 billion in 2024 to an astounding $230.15 billion by 2032 1 12.1% Key Drivers: Changing consumer demographics, increased demand for health-focused devices (e.g., smartwatc
Slide 10: Disrupt and Democratize the ECG market
Disrupt and Democratize the ECG market Our Goal to monetize One Billion ECG files in the next decade. We believe with the Neuralized ECG, we are redefining the future of cardiac care - soon, monitoring deep heart health data will be as effortless as checking your pulse. We believe that over 100 bill
Slide 11: Milestones
Milestones People ● Scale from 5 to 50+ Products ● MaxYield ECG, Insight 360, CardioYield Technology & Intellectual Property ● IP Strategy and Update Regulatory & Quality Management ● FDA, Health Canada, Jamaica Commercial Traction ● Pipeline, Pilots and Deals
Slide 12: People: Building the best team in the industry
People Building the best team in the industry Capital‑efficient operating model designed for scalable growth AIML Team Structure (CY Q4, 2025) ● 54 total people across the AIML orbit ● Engagement Mix ○ 22 Full-Time (12 direct, 10 strategic partners) ○ 27 Part-Time / Consultants ○ 5 Medical Advisors
Slide 13: People: Where the Team Is Deployed
People Building the best team in the industry Where the Team Is Deployed 🧠 Product, AI & Engineering — 18 🏛 Leadership, Board & Medical Advisors — 7 ● Neural Cloud, MaxYield™, AI/ML, software ● Strategy, governance, clinical credibility, & platform scalability partnerships 🩺 Clinical Operations…
Slide 14: Product Suite
Product Suite ECG Data Intelligence Platform A modular software platform designed to process, organize, and present ECG data to support clinical workflows, research, and wellness applications. Software engine designed to process ECG signals and extract structured signal features for downstream analy
Slide 15: We are by Design Device Agnostic
We are by Design Device Agnostic Market Size & Growth ● ECG Equipment: $8.62B (2023); 7.2% CAGR (2024–2030)* ● Ambulatory cardiac monitoring: $6.42B (2023); 10.4% CAGR (2023–2030)* ● Mobile ECG devices: $4.13B (2024); 10.1% CAGR (2025–2032)** ● Smart wearable ECG monitors: $1.98B (2024); 10.33% CAGR
Slide 16: Slide 16
Slide 17: Introducing MaxYield
Introducing MaxYield™ Our X-Factor
Slide 18: MaxYield
MaxYield™ Maximum Diagnostic Yield ● Our flagship technology - our “X-Factor” - is a Signal Processing Neural Network (NN), that expertly isolates and extracts an ECG waveform from all the noise in a signal. ● Our Signal Intelligence algorithms are device agnostic, capable of identifying and analyzi
Slide 19: MaxYield - Maximum Diagnostic Yield
MaxYield™ - Maximum Diagnostic Yield We make Every Beat Count: Isolates clean signals We have created a new Gold Standard: Beat-by-Beat Analysis & Noise Reduction from noisy data for Actionable Information
Slide 20: MaxYield - Immediately Reduce or Eliminate Artifacts
MaxYield - Immediately Reduce or Eliminate Artifacts “By instantly filtering out artifacts, we significantly reduce time spent identifying false signals that are often mistaken for true cardiac events.” In many current systems, artifacts are frequently misinterpreted as cardiac events, especially in l
Slide 21: White Paper
White Paper https://www.theneuralcloud.com/maxyield-white-paper ● MaxYield vs. 15 Registered Cardiology Technologists ○ Our White Paper compared MaxYield’s neural network P, QRS, and T Wave detection with experts - ranking second only to the top human expert. ● Increase Technician Throughput ○ Tradi
Slide 22: Insight360
Insight360
Slide 23: Comprehensive ECG Reporting
Comprehensive ECG Reporting Data Presentation Offers detailed cardiac metrics - peaks, onsets, offsets, intervals, and amplitudes - in both CSV and PDF report formats. Statistical Analysis Introduces advanced statistical analysis for ECG data, providing unprecedented insights and observations to end
Slide 24: Goals of ECG Support Tool
Goals of ECG Support Tool Faster Analysis Times: ● Reduces analysis time from hours to minutes, optimizing efficiency, particularly in remote settings. Improved Diagnostic Accuracy And Yield: ● By providing automated, precise annotations, Neural Cloud aims to deliver better clinical outcomes and mor
Slide 25: CardioYield
Al/ML INNOVATIONS INC. fa Lo
Slide 26: CardioYield
CardioYield™ Holter Reporting Interface for Technicians Report Generation ● More Holter reports. ● Same staff. Same devices. Increased Throughput ● Faster report prep with technician-led validation. Outcome - Net Benefits ● Higher capacity, ● Lower friction, ● Scalable growth. Designed by ElectroPhy
Slide 27: The Holter Reality in Most Clinics Today
The Holter Reality in Most Clinics Today 3–5 Holter cases per tech per day ● Long review times and manual corrections limit daily output. ● “Every second, more than 9 medical ECGs are performed worldwide” Backlogs & delayed reports ● Extended turnaround times frustrate both cardiologists and patient
Slide 28: How CardioYield Improves Holter Workflow
How CardioYield Improves Holter Workflow Today With CardioYield 1. Hours per report 1. Reports in minutes, not hours 2. Manual event hunting & beat correction 2. Event-led review: validate, don’t hunt 3. Noise-driven false positives 3. Neuralized signals with noise removed upfront 4. Limited cases p
Slide 29: How CardioYield Fits the Existing Clinic Workflow
How CardioYield Fits the Existing Clinic Workflow “Neuralize” Upload Review & Validate Report & Export with MaxYield Holter, Ambulatory, Cleans ECG & Quantifies: Technicians use CardioYield Structured report or other long-form fields auto- populate ● P/QRS/T Wave ● Review flagged events ECGs and expo
Slide 30: Getting Started With CardioYield
Take The Next Step Getting Started With CardioYield No hardware changes required CardioYield is device-agnostic & works with your current Holter devices Simple data integration We configure import formats for your existing recorders Pilot & benchmark Compare CardioYield vs. your current workflow on
Slide 31: Expert Testimonials
Expert Testimonials "Neural Cloud's Holter analysis "The advanced algorithm identifies "Its superior artifact filtering software is revolutionary. Unlike Atrioventricular blocks at varying drastically reduces noise, others limited to basic QRS degrees, improving accuracy and producing clinically acc
Slide 32: One ECG Data Intelligence Platform - Multiple Markets
One ECG Data Intelligence Platform - Multiple Markets Quicker: Rapid turnaround, quantified beat-by-beat tabulation accelerates analysis & clinical decision-making. Cheaper: Scalable cloud-based AI reduces costs by automating ECG interpretation. Better: Advanced de-noising isolates vital data from s
Slide 33: Technology & IP - Patents & Trademarks
Technology & IP - Patents & Trademarks Securing Technological Innovation We have been granted a broad patent, with little prior art based upon submissions 12 months ago. Our latest filings are 10 X in specificity. Working with Wolf Greenfield Sack, one of the world’s best Life Sciences Intellectual
Slide 34: Regulatory Pathway & Quality Framework
Regulatory Pathway & Quality Framework United States (FDA) ● MaxYield™ — FDA 510(k) pathway ● CardioYield™ — FDA 510(k) pathway Canada (Health Canada) ● MaxYield™ — Class II Medical Device pathway ● CardioYield™ — Class II Medical Device pathway Caribbean (Jamaica) ● CardioYield™ — Regulatory Submis
Slide 35: Commercial Traction for Q4, CY 2025
Commercial Traction for Q4, CY 2025 It was a very busy and productive quarter. ● September 30th, 2025 AIML and BC Brain Wellness Program Launch Pilot to Explore the Heart–Brain Connection ● October 7th, 2025 AIML Subsidiary NeuralCloud Solutions and Toronto Heart Centre Launch a Pilot Program to Tes
Slide 36: Traction for Q4, CY 2025 continued
Traction for Q4, CY 2025 continued… It was a very busy and productive quarter. ● November 24th, 2025 AIML subsidiary Neural Cloud begins pilot at The Hospital for Sick Children (SickKids) to Advance AI-Enabled Pediatric Cardiac Care ○ Pilot Project to Explore AI-Driven ECG Signal Processing and Pred
Slide 37: The Year Ahead: Executing Across Five Value Drivers
The Year Ahead … Executing Across Five Value Drivers 1. Commercial Traction & Revenue ● Convert pilots and term sheets into recurring commercial contracts ● Expand clinic footprint in anticipation of regulatory clearances ● License MaxYield™, CardioYield™, and Insight360™ across clinical, research,
Slide 38: Capital Structure
Capital Structure 253.9 Million 16 Million Shares Outstanding Options 190.7 Million 460.6 Million Warrants Outstanding Fully Diluted CSE: AIML OTCQB: AIMLF FWB: 42FB
Slide 39: Ask Me Anything
a Al/ML JP INNOVATIONS LS INC.
AI/ML Innovations — Investor Presentation (December 2025) on 6ix